51 related articles for article (PubMed ID: 12164019)
1. Calcimimetic agents for the treatment of secondary hyperparathyroidism.
Dykeman J
CANNT J; 2002; 12(2):27-9. PubMed ID: 12164019
[No Abstract] [Full Text] [Related]
2. Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism.
Mansour J; Shahapuni I; Mailliez S; Aghai R; Fournier A
Nat Clin Pract Nephrol; 2007 Apr; 3(4):E2; discussion E3. PubMed ID: 17389886
[No Abstract] [Full Text] [Related]
3. RenaGel efficacy in severe secondary hyperparathyroidism.
Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
[TBL] [Abstract][Full Text] [Related]
4. Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up.
Shuja SB; Raja RM
Adv Perit Dial; 2003; 19():231-5. PubMed ID: 14763069
[TBL] [Abstract][Full Text] [Related]
5. [Cimetidine therapy of hyperparathyroidism?].
Windeck R; Benker G; Hoff HG; Reinwein D
Dtsch Med Wochenschr; 1981 Oct; 106(43):1433-5. PubMed ID: 7285829
[No Abstract] [Full Text] [Related]
6. [Medical-surgical integrated approach in the treatment of non-paraneoplasic hyperparathyroidism: our experience].
Pulvirenti D; Aikaterini T; Campagna A; Ignaccolo L; Giustolisi N; Costa E
Clin Ter; 2008; 159(5):307-10. PubMed ID: 18998031
[TBL] [Abstract][Full Text] [Related]
7. Humoral hypercalcemia of malignancy (pseudohyperparathyroidism).
Peter SA
N Y State J Med; 1985 Jun; 85(6):242. PubMed ID: 3860751
[No Abstract] [Full Text] [Related]
8. A radioimmunoassay for parathyroid hormone in man. II. Measurement of parathyroid hormone concentrations in human plasma by means of a radioimmunoassay for bovine hormone.
Lequin RM; Hackeng WH; Schopman W
Acta Endocrinol (Copenh); 1970 Apr; 63(4):655-66. PubMed ID: 5468287
[No Abstract] [Full Text] [Related]
9. [Clinical analysis of time-course changes in minerals and parathyroid hormone levels during treatment with phosphate binders in hemodialysis patients with secondary hyperparathyroidism].
Yokoyama T; Onodera Y; Mano T
Clin Calcium; 2005 Sep; 15 Suppl 1():125-30; discussion 130-1. PubMed ID: 16272644
[TBL] [Abstract][Full Text] [Related]
10. Extended-release calcifediol (Rayaldee) for secondary hyperparathyroidism.
Med Lett Drugs Ther; 2017 Feb; 59(1515):36-37. PubMed ID: 28222063
[No Abstract] [Full Text] [Related]
11. Which of the K/DOQI guidelines for bone disease in dialysis patients should be changed?
Gal-Moscovici A; Sprague SM; Hutchison AJ; Shah N; Piraino B; Cunningham J
Semin Dial; 2007; 20(1):24-32. PubMed ID: 17244115
[No Abstract] [Full Text] [Related]
12. [Calcimimetics and secondary uremic hyperparathyroidism. The Danish Society of Nephrology].
Ølgaard K
Ugeskr Laeger; 2003 Mar; 165(12):1245. PubMed ID: 12701295
[No Abstract] [Full Text] [Related]
13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
14. [Surgical treatment of refractory hyperparathyroidism and usefulness of the intraoperative PTH].
Pino Rivero V; González Palomino A; Pantoja Hernández CG; Mora Santos ME; Guerra Camacho M; Carrasco Claver F; Barrantes Celaya G
Acta Otorrinolaringol Esp; 2007 Feb; 58(2):39-42. PubMed ID: 17371679
[TBL] [Abstract][Full Text] [Related]
15. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
16. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy.
Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M
Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism.
Felsenfeld AJ; Rodríguez M; Aguilera-Tejero E
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1283-305. PubMed ID: 17942777
[TBL] [Abstract][Full Text] [Related]
18. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
19. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Brown AJ; Slatopolsky E
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
[TBL] [Abstract][Full Text] [Related]
20. The influence of the progression of secondary hyperparathyroidism on the set point of the parathyroid hormone-calcium curve.
Bas S; Aguilera-Tejero E; Bas A; Estepa JC; Lopez I; Madueño JA; Rodriguez M
J Endocrinol; 2005 Jan; 184(1):241-7. PubMed ID: 15642800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
